MOTS-c: What the Research Says

What is MOTS-c?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide with an unusual origin: it is encoded not in the nuclear genome but in mitochondrial DNA, within the gene for 12S ribosomal RNA. It was discovered by the groups of Pinchas Cohen and Changhan Lee at the University of Southern California and described in 2015 as a mitochondrial signalling peptide that communicates the metabolic state of mitochondria to the rest of the cell. Because of its role in energy metabolism and ageing, MOTS-c is among the most discussed molecules in longevity research — which is why PeptaMED lists research-grade MOTS-c in the Longevity category.

Key research findings

The discovery — Lee et al., 2015 (Cell Metabolism). The original publication showed that MOTS-c acts mainly on skeletal muscle, activates AMPK — the cell’s central energy sensor — by inhibiting the folate cycle and accumulating AICAR, improves insulin sensitivity, and protects mice from diet-induced obesity.

The exercise-mimetic hypothesis — Reynolds et al., 2021 (Nature Communications). This study documented that physical exercise raises MOTS-c in human plasma and muscle, and that administering the peptide to aged mice improved their physical capacity and treadmill endurance. It is this work that cemented the exercise-mimetic label, although the authors explicitly stress that the interventional findings come from animal models.

Nuclear translocation under stress — Kim et al., 2018. Under metabolic stress, MOTS-c translocates to the cell nucleus and regulates the expression of antioxidant-response genes (including the NRF2 axis) — the first demonstration of a mitochondrially encoded peptide acting as a nuclear transcriptional regulator.

Human genetics. The naturally occurring K14Q variant (the m.1382A>C polymorphism), common in East Asian populations, has been associated in observational studies with higher type 2 diabetes risk in physically inactive men — indirect but human evidence of the peptide’s metabolic role. Endogenous MOTS-c levels decline with age.

Clinical proof of concept. The analogue CB4211 (CohBar) completed a phase 1a/1b trial — the first clinical test of a mitochondria-derived peptide — with signals on liver-fat and metabolic markers, but the programme did not continue after the company restructured. For MOTS-c itself, there are no controlled clinical trials.

Safety profile in the research

Full candour is required here: virtually all MOTS-c data come from cell cultures and rodents, where the peptide has been well tolerated within the protocols used. Systematic human safety data for MOTS-c itself do not exist — the CB4211 phase 1 programme concerned a modified analogue and does not transfer directly. Human pharmacokinetics, immunogenicity and long-term effects are unknown.

Open questions

The short half-life and optimal delivery route remain unresolved technical questions. It is unclear whether the effects seen in aged mice translate to humans, how MOTS-c interacts with real training stimuli, and where it stands relative to other peptides studied in the context of ageing, such as epitalon. Standardising the measurement of endogenous levels is another open methodological problem in the literature.

Metabolic detail and human observations

At the cellular level, MOTS-c increases glucose uptake in skeletal muscle through enhanced GLUT4 translocation and rewires metabolism via the folate–methionine cycle — an unusual mechanism that sets it apart from classical AMPK activators. Observational studies in humans add context: circulating MOTS-c levels correlate with insulin sensitivity in some cohorts and are lower in obesity and type 2 diabetes, while plasma concentrations decline markedly with age — one reason the peptide is discussed as a potential biomarker of mitochondrial ageing. Technical challenges abound, however: the plasma half-life is short (on the order of minutes), so animal protocols rely on frequent injections, and different immunoassays (ELISA kits) report divergent absolute values, which makes cross-laboratory comparison difficult. Active research fields also include sarcopenia, bone metabolism (mouse osteoporosis models) and the relationship between cold exposure, brown adipose tissue and mitochondria-derived peptides. All of this makes MOTS-c fertile ground for fundamental work — with the explicit caveat that translation to humans is still ahead.

Specifications

Laboratory purity certificates are available in the lab testing section, and the peptide calculator supports reconstitution maths in research settings.

Disclaimer: This article is for informational and educational purposes only and summarises published scientific research. PeptaMED products are intended exclusively for laboratory and research use and are not approved for human or veterinary use, diagnosis or treatment. Nothing here constitutes medical advice.

Products mentioned in this article

MOTS-c | 10mg | Dosing Pen€74,00View product →